Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines

Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines
Camp4 showcases RNA breakthrough

Camp4 Therapeutics Corp is set to present its latest research on regulatory RNAs aimed at increasing gene expression in haploinsufficiency diseases at the 2026 Cancer Epigenetics Institute Symposium, hosted by Fox Chase Cancer Center and sponsored by Biomodalhq.

Dan Tardiff, PhD, Chief Scientific Officer of Camp4 Therapeutics Corp, will highlight the company’s approach to deploying regulatory RNAs as a novel solution for conditions where gene activity is insufficient. The presentation underscores ongoing innovation in epigenetic therapies and could signal future advances for rare disease treatment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.